Clinical trial
Neoadjuvant Herceptin in Patients With Breast Cancer
NCT00133796 · Mothaffar Rimawi, Other · Terminated
Key facts
| NCT number | NCT00133796 |
|---|---|
| Title | Neoadjuvant Herceptin in Patients With Breast Cancer |
| Official title | A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer |
| Lead sponsor | Mothaffar Rimawi, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | BREAST CANCER |
| Intervention type | Drug |
| Interventions | Herceptin |
| Enrollment | 40 |
| Start date | Oct 1, 2001 |
| Primary completion | Sep 1, 2005 |
| Completion | Apr 1, 2007 |
| First posted | Aug 24, 2005 |
| Last update posted | Feb 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: